Equity Overview
Price & Market Data
Price: $6.84
Daily Change: +$0.21 / 3.07%
Daily Range: $6.48 - $6.89
Market Cap: $424,109,408
Daily Volume: 114,981
Performance Metrics
1 Week: 3.79%
1 Month: 9.44%
3 Months: 25.05%
6 Months: -14.50%
1 Year: -25.97%
YTD: -16.79%
Company Details
Employees: 106
Sector: Health technology
Industry: Biotechnology
Country:
Details
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer, as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.